Treatment of Endometriosis with Transvaginal Ultrasound-Guided Drainage and Recombinant Interleukin-2 Left in the Cysts: A Third Clinical Trial

2010 ◽  
Vol 69 (3) ◽  
pp. 203-211 ◽  
Author(s):  
Pedro Acién ◽  
Irene Velasco ◽  
Maribel Acién ◽  
Francisco Quereda
Keyword(s):  
Clinical Trial ◽  
Transvaginal Ultrasound ◽  
Interleukin 2 ◽  
Ultrasound Guided ◽  
Recombinant Interleukin 2

Treatment of Endometriosis with Transvaginal Ultrasound-Guided Drainage under GnRH Analogues and Recombinant Interleukin-2 Left in the Cysts

2005 ◽  
Vol 60 (4) ◽  
pp. 224-231 ◽  
Author(s):  
Pedro Acién ◽  
Gloria Pérez-Albert ◽  
Francisco J. Quereda ◽  
Marisa Sánchez-Ferrer ◽  
Ana García-Almela ◽  
...  
Keyword(s):  
Transvaginal Ultrasound ◽  
Interleukin 2 ◽  
Ultrasound Guided ◽  
Gnrh Analogues ◽  
Recombinant Interleukin 2

A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.

1989 ◽  
Vol 7 (2) ◽  
pp. 276-284 ◽  
Author(s):  
S P Creekmore ◽  
J E Harris ◽  
T M Ellis ◽  
D P Braun ◽  
I I Cohen ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Phase I ◽  
Peripheral Blood ◽  
Immune Modulation ◽  
Eastern Cooperative Oncology Group ◽  
Interleukin 2 ◽  
Phase I Clinical Trial ◽  
Treatment Modalities ◽  
Prolonged Treatment ◽  
Recombinant Interleukin 2

Recombinant interleukin-2 (rIL-2) (NSC# 600664; Hoffmann-La Roche, Inc., Nutley, NJ) was studied in a phase I clinical trial in 33 patients with advanced, measureable cancer of the colon or malignant melanoma, Eastern Cooperative Oncology Group (ECOG) performance status O-1, and no prior chemotherapy or radiotherapy. The goal of the study was to identify a dose and schedule of IL-2 to generate maximal immune modulation with tolerable toxicity. Such a regimen might allow the addition of other treatment modalities and/or prolonged treatment duration in later trials. Each patient received IL-2 as a continuous 24-hour infusion once weekly for 4 weeks and then twice weekly for 4 weeks. Five treatment groups received from 10(3) U/m2 to 3 x 10(7) U/m2 per 24-hour infusion. The maximal tolerated dose was 3 x 10(7) U/m2/d twice weekly. Patients treated twice weekly at 1 x 10(7) and 3 x 10(7) U/m2/d had immune modulation in terms of lymphocytosis, eosinophilia, increased natural killer (NK) activity, and elevated numbers of peripheral blood mononuclear cells expressing CD16, OKT10/Leu-17, and Leu-19 surface markers. Endogenous generation of peripheral blood lymphokine-activated killer (LAK) activity was demonstrated by lysis of NK-resistant Daudi targets, in patients treated at 3 x 10(7) U/m2/d. Biochemical and hematological abnormalities were moderate and reversible. Clinical toxicity included hypotension, myalgia, arthralgia, stomatitis, fever, fatigue, nausea, headache, chills, diarrhea, and oliguria at high doses. Cardiovascular toxicity was tolerable for most patients and reversed after IL-2 was stopped. Two of six melanoma patients at 3 x 10(7) U/m2/d achieved partial responses by the end of the eighth week. This IL-2 schedule appears to produce potentially clinically useful immune enhancement with tolerable toxicity.

Phase 1 Clinical Trial of Recombinant Interleukin-2: A Comparison of Bolus and Continuous Intravenous Infusion

1989 ◽  
Vol 7 (3) ◽  
pp. 213-223 ◽  
Author(s):  
Peter C. Kohler ◽  
Jacquelyn A. Hank ◽  
Karen H. Moore ◽  
Barry Storer ◽  
Robin Bechhofer ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Intravenous Infusion ◽  
Phase 1 ◽  
Interleukin 2 ◽  
Continuous Intravenous Infusion ◽  
Phase 1 Clinical Trial ◽  
Recombinant Interleukin 2

The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerised assessments

1996 ◽  
Vol 32 (13) ◽  
pp. 2275-2283 ◽  
Author(s):  
L.G. Walker ◽  
K.P. Wesnes ◽  
S.D. Keys ◽  
M.B. Walker ◽  
J. Lolley ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Interleukin 2 ◽  
Controlled Clinical Trial ◽  
Cognitive Effects ◽  
Recombinant Interleukin 2
Sign in / Sign up

Export Citation Format

Share Document